Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 3 benralizumab study in children with EGPA or HES
MOH_2026-04-06_015751Phase 3Not yet recruiting
- Sponsor
- AstraZeneca
- Start
- Apr 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of benralizumab in hypereosinophilic syndrome (HES) and eosinophilic granulomatosis with polyangiitis (EGPA) (3 arms), sponsored by AstraZeneca. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
benralizumab
03
Conditions
hypereosinophilic syndrome (HES)eosinophilic granulomatosis with polyangiitis (EGPA)
Beyond the preview
Go deeper on MOH_2026-04-06_015751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-04-06_015751.